The presence of an isocitrate dehydrogenase (IDH) mutation might potentially increase glioma cells’ sensitivity to oxidative damage from radiation treatment and molecular targets, e.g., IDH inhibitors [7]. Here, IDH3A is linked to central nervous system cancer.